Beyond the regulatory level, a well-recognised challenge for companies launching drugs in orphan dis...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreAmgen’s Lumykras (sotorasib) has become the first active new technology to come through the Innova...
Read moreThe National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s Zej...
Read moreOn 28th February 2022, Health and Social Care Secretary Sajid Javid launched England’s first Rare...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreThe CDF allows patients to access a new treatment while further data is collected on its clinical an...
Read moreIn a statement the ICR said that it welcomes some of the changes, but that it wants to “see furthe...
Read moreThe news comes after the health service negotiated a “significant confidential discount” to the ...
Read moreNICE require a broad range of evidence to be included within the reimbursement dossier, including cl...
Read more